Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지

Impact of Cyclooxygenase-2 Expression on the Survival of Glioblastoma

다형성아교모세포종 환자에서 Cyclooxygenase-2 발현이 생존율에 미치는 영향

  • Choi, Young-Min (Departments of Radiation Oncology, Dong-A University School of Medicine) ;
  • Kim, Dae-Cheol (Departments of Pathology, Dong-A University School of Medicine) ;
  • Kim, Ki-Uk (Departments of Neurosurgery, Dong-A University School of Medicine) ;
  • Song, Young-Jin (Departments of Neurosurgery, Dong-A University School of Medicine) ;
  • Lee, Hyung-Sik (Departments of Radiation Oncology, Dong-A University School of Medicine) ;
  • Hur, Won-Joo (Departments of Radiation Oncology, Dong-A University School of Medicine) ;
  • Choi, Sun-Seob (Departments of Diagnostic Radiology, Dong-A University School of Medicine) ;
  • Seo, Su-Yeong (Departments of Microbiology, Dong-A University School of Medicine)
  • 최영민 (동아대학교 의과대학 방사선종양학교실) ;
  • 김대철 (동아대학교 의과대학 병리학교실) ;
  • 김기욱 (동아대학교 의과대학 신경외과학교실) ;
  • 송영진 (동아대학교 의과대학 신경외과학교실) ;
  • 이형식 (동아대학교 의과대학 방사선종양학교실) ;
  • 허원주 (동아대학교 의과대학 방사선종양학교실) ;
  • 최순섭 (동아대학교 의과대학 영상의학교실) ;
  • 서수영 (동아대학교 의과대학 미생물학교실)
  • Published : 2007.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To investigate the degree and effect of cyclooxygenase (COX)-2 expression on the survival of patients with glioblastoma multiforme (GM). Materials and Methods: Between 1997 and 2006, thirty consecutive GM patients treated with surgery and postoperative radiotherapy (dose range: $44{\sim}65.1$ Gy, median dose: 61.2 Gy) were included in the study. Three patients were excluded that discontinued radiotherapy before receiving a dose of 40 Gy due to mental deterioration. The expression of the COX-2 protein in surgical specimens was examined by immunohistochemical analysis. Survival analysis and verification were performed with respect to sex, age, performance status, resection extent, radiotherapy dose, and degree of COX-2 expression using the Kaplan-Meier method and the log rank test. Results: The median length of follow-up was 13.3 months (range:$6{\sim}83$ months). Staining for COX-2 was positive in all patient samples. Staining for COX-2 that was positive for over 75% of the tumor cells was found in 24 patients. Staining for COX-2 that was positive in less than 25% of tumor cells was found in 3 patients (10.0%), staining for COX-2 that was positive in 25 to 50% of tumor cells was found in 1 patient (3.3%), staining for COX-2 that was positive in 50 to 75% of tumor cells was found in 2 patients (6.7%) and staining for COX-2 that was positive in 75 to 100% of tumor cells was found in 24 patients (80.0%). The median survival and two-year survival rate were 13.5 months and 17.5%, respectively. The survival rate was influenced significantly by the degree of resection (tumor removal by 50% or more) and radiotherapy dose (59 Gy or greater) (p<0.05). The median survival of patients with staining for COX-2 that was positive in less than 75% of tumor cells and in at least 75% of tumor cells was 15.5 and 13.0 months, respectively (p>0.05), and the two-year survival for these groups was 33.3 and 13.3%, respectively (p>0.05). Conclusion: The absence of a statistical correlation between the degree of COX-2 expression and survival in GM patients, despite the high rate of COX-2 positive tumor cells in the GM patient samples, requires further studies with a larger series to ascertain the prognostic value of the degree of COX-2 expression in GM patients.

목적 :다형성아교모세포종 환자들에서 cyclooxygenase-2 (COX-2) 단백의 발현 정도와 생존율에 미치는 영향을 조사하고자 한다. 대상 및 방법: 1997년부터 2006년까지 다형성아교모세포종으로 수술 및 방사선치료를 받은 환자들 중에서, 의식 상태의 악화로 40 Gy 전에 방사선치료가 중단된 3명을 제외한 30명을 대상으로 하였다. 조직에서의 COX-2의 발현은 면역조직화학염색으로 검사하였다. 생존 분석과 성별, 나이, 활동도, 수술 정도, 방사선량, COX-2 발현 정도 등이 생존율에 미치는 영향을 Kaplan Meier 법과 log rank test로 분석 및 검증하였다. 결과: 중앙추적관찰기간은 13.3개월이었다($6{\sim}83$). 전체 환자들에서 COX-2의 발현이 관찰되었고, 종양 세포의 75%이상에서 COX-2가 양성이었던 환자가 24명이었다. 종양 세포의 25%미만, 3명(10.0%); $25{\sim}50%$, 1명(3.3%); $50{\sim}75%$, 2명(6.7%); $75{\sim}100%$, 24명(80.0%). 중앙생존기간이 13.5개월이었고, 2년 생존율은 17.5%없다. 수술 정도(50% 이상 종양 제거)와 방사선량(59 Gy 이상 조사)이 생존율에 유의하게 영향을 주었다(p<0.05). 종양 세포의 75% 미만에서 COX-2가 발현되었던 환자군과 75% 이상에서 발현되었던 환자군에서 중앙생존기간은 각각 15.5개월과 13.0개월이었고(p>0.05), 2년 생존율은 각각 33.3%와 13.3%없다(p>0.05). 결론: 다형성아교모세포종에서의 COX-2 양성도는 높았지만, 다형성아교모세포종 환자들에서 COX-2 발현의 정도와 생존율 간에는 통계적인 유의성이 없었으므로, 향후 보다 많은 환자들을 대상으로 COX-2 발현 정도가 생존율에 미치는 영향에 대한 연구가 필요하다.

Keywords

References

  1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996 https://doi.org/10.1056/NEJMoa043330
  2. Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 2004;60:853-860 https://doi.org/10.1016/j.ijrobp.2004.04.011
  3. Lin MT, Lee RC, Yang PC, Ho FM, Kuo ML. Cyclooxygenase- 2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 2001; 276:48997-49002 https://doi.org/10.1074/jbc.M107829200
  4. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998;58: 362-366
  5. Chinery R, Coffey RJ, Graves-Deal R, et al. Prostaglandin J2 and 15-deoxy-delta12,14-prostaglandin J2 induce proliferation of cyclooxygenase-depleted colorectal cancer cells. Cancer Res 1999;59:2739-2746
  6. Sawaoka H, Kawano S, Tsuji S, Tsujii M, Murata H, Hori M. Effects of NSAIDs on proliferation of gastric cancer cells in vitro: possible implication of cyclooxygenase-2 in cancer development. J Clin Gastroenterol 1998;27(Suppl 1):S47-52 https://doi.org/10.1097/00004836-199807000-00009
  7. Tomozawa S, Tsuno NH, Sunami E, et al. Cyclooxygenase- 2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 2000;83:324-328 https://doi.org/10.1054/bjoc.2000.1270
  8. Kakiuchi Y, Tsuji S, Tsujii M, et al. Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis. Cancer Res 2002; 62:1567-1572
  9. Uefuji K, Ichikura T, Mochizuki H. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res 2000; 6:135-138
  10. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-1311
  11. Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA, Worley PF. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 1993;11:371-386 https://doi.org/10.1016/0896-6273(93)90192-T
  12. Yasojima K, Schwab C, McGeer EG, McGeer PL. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res 1999;830:226-236 https://doi.org/10.1016/S0006-8993(99)01389-X
  13. Kirschenbaum A, Liotta DR, Yao S, et al. Immunohistochemical localization of cyclooxygenase-1 and cyclooxygenase- 2 in the human fetal and adult male reproductive tracts. J Clin Endocrinol Metab 2000;85:3436-3441 https://doi.org/10.1210/jc.85.9.3436
  14. Deininger MH, Weller M, Streffer J, Mittelbronn M, Meyermann R. Patterns of cyclooxygenase-1 and -2 expression in human gliomas in vivo. Acta Neuropathol 1999;98: 240-244 https://doi.org/10.1007/s004010051075
  15. Joki T, Heese O, Nikas DC, et al. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res 2000;60: 4926-4931
  16. Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res 2001;61: 4375-4381
  17. Buccoliero AM, Caldarella A, Gheri CF, et al. Inducible cyclooxygenase (COX-2) in glioblastoma--clinical and immunohistochemical (COX-2-VEGF) correlations. Clin Neuropathol 2006;25:59-66
  18. Prayson RA, Castilla EA, Vogelbaum MA, Barnett GH. Cyclooxygenase-2 (COX-2) expression by immunohistochemistry in glioblastoma multiforme. Ann Diagn Pathol 2002; 6:148-153 https://doi.org/10.1053/adpa.2002.33900
  19. Kardosh A, Blumenthal M, Wang WJ, Chen TC, Schonthal AH. Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines. Cancer Biol Ther 2004;3:55-62 https://doi.org/10.4161/cbt.3.1.571
  20. Nam DH, Park K, Park C, et al. Intracranial inhibition of glioma cell growth by cyclooxygenase-2 inhibitor celecoxib. Oncol Rep 2004;11:263-268
  21. Petersen C, Petersen S, Milas L, Lang FF, Tofilon PJ. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin Cancer Res 2000;6: 2513-2520
  22. Pyo H, Choy H, Amorino GP, et al. A selective cyclooxygenase- 2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxy-genase-2. Clin Cancer Res 2001;7:2998-3005
  23. Karim A, McCarthy K, Jawahar A, Smith D, Willis B, Nanda A. Differential cyclooxygenase-2 enzyme expression in radiosensitive versus radioresistant glioblastoma multiforme cell lines. Anticancer Res 2005;25:675-679
  24. Simpson JR, Horton J, Scott C, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 1993;26:239-244 https://doi.org/10.1016/0360-3016(93)90203-8
  25. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001;95:190-198 https://doi.org/10.3171/jns.2001.95.2.0190
  26. Cho JH, Lee CG, Kim KJ, et al. Radiation dose-escalation trial for glioblastomas with 3D-conformal radiotherapy. J Kor Soc Ther Radiol Oncol 2004;22:237-246
  27. Sandberg-Wollheim M, Malmstrom P, Stromblad LG, et al. A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer 1991;68:22-29 https://doi.org/10.1002/1097-0142(19910701)68:1<22::AID-CNCR2820680105>3.0.CO;2-2
  28. Kowalczuk A, Macdonald RL, Amidei C, et al. Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery 1997;41: 1028-1036 https://doi.org/10.1097/00006123-199711000-00004
  29. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979;5:1725-1731 https://doi.org/10.1016/0360-3016(79)90553-4
  30. Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer 1991;64:769-774 https://doi.org/10.1038/bjc.1991.396
  31. Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1989;16:1405-1409 https://doi.org/10.1016/0360-3016(89)90941-3
  32. Chang CH, Horton J, Schoenfeld D, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 1983;52:997-1007 https://doi.org/10.1002/1097-0142(19830915)52:6<997::AID-CNCR2820520612>3.0.CO;2-2